CHICAGO STAR: T-Neuro Pharma to Presents Expanded Alzheimer’s Disease Blood Biomarker Assay at Clinical Trials on Alzheimer’s Disease (CTAD) conference
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today that it will present new research on its Diagnostic Biomarker assay for Alzheimer’s at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference. The poster presentation, scheduled for Oct….
BIOSPACE: T-Neuro Pharma’s Trailblazing Alzheimer’s Research Receives Acclaim in PNAS Commentary
T-Neuro Pharma, a leading biotechnology research company dedicated to developing innovative therapies for neurodegenerative diseases, announced that its groundbreaking research on Alzheimer’s disease has been highlighted in a commentary published in the Proceedings of the National Academy of Sciences USA (PNAS), a peer-reviewed journal of…
BIZJOURNAL: Albuquerque biopharma startup eyes investment after research paper publishes
An Albuquerque biopharmaceutical startup hopes publishing a “remarkable” study on its approach to detecting and diagnosing Alzheimer’s disease can help the company attract more investment and reach commercial success. Read the Full Article
JOURNAL OF ALZHEIMER’S DISEASE: Can Immunity Impact Alzheimer’s Disease?
Evolutionary Selection of APOE 4 Encourages Increased Focus on Immunity in Alzheimer’s Disease By: Christopher J. Wheeler Abstract. Smith and Ashford present a compelling hypothesis on evolution of APOE alleles, namely that 4 prevalence is mediated by immune selection pressure against enteric pathogens. While the…